The New England journal of medicine
-
Eculizumab is a humanized monoclonal antibody that targets complement protein C5 and inhibits terminal complement-mediated hemolysis associated with paroxysmal nocturnal hemoglobinuria (PNH). The molecular basis for the poor response to eculizumab in a small population of Japanese patients is unclear. ⋯ The functional capacity of C5 variants with mutations at Arg885, together with their failure to undergo blockade by eculizumab, account for the poor response to this agent in patients who carry these mutations. (Funded by Alexion Pharmaceuticals and the Ministry of Health, Labor, and Welfare of Japan.).
-
A 48-year-old woman presented to the emergency department with severe otalgia of 1 day's duration. Bloody otorrhea in the left ear was noted after her hearing aid was removed. A video shows findings in the auditory canal.
-
Case Reports Interactive Tutorial
Interactive medical case: wasting away.
This interactive feature presents the case of a 40-year-old woman with pain, weakness, and poor oral intake. She had had a gradual onset of bilateral flank pain spreading to her lower back, abdomen, and extremities. Test your diagnostic and therapeutic skills at NEJM.org.
-
Despite knowing that heart disease kills more women each year than all cancers combined, most women fear breast cancer far more - and their health-related behavior reflects this difference. If our sense of risk is less about fact than about feeling, how do we adjust it?